The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
 
Tsuyoshi Hata
Honoraria - Johnson & Johnson; Taiho Pharmaceutical; TERUMO
Consulting or Advisory Role - Johnson & Johnson; Olympus
Research Funding - Bayer (Inst)
 
Naotoshi Sugimoto
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Solasia Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Nobuyoshi Ohara
No Relationships to Disclose
 
Masaaki Miyo
No Relationships to Disclose
 
Shinichi Yoshioka
No Relationships to Disclose
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Atsushi Naito
No Relationships to Disclose
 
Mitsuyoshi Tei
No Relationships to Disclose
 
Hiroshi Tamagawa
No Relationships to Disclose
 
Ken Konishi
No Relationships to Disclose
 
Genta Sawada
No Relationships to Disclose
 
Katsuki Danno
No Relationships to Disclose
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Norikatsu Miyoshi
No Relationships to Disclose
 
Hidekazu Takahashi
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Kohei Murata
No Relationships to Disclose
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Hidetoshi Eguchi
No Relationships to Disclose